|
|
|
| Analysis of the Effect and Adverse Events of Anlotinib Combined with PD-1 Monoclonal Antibody Second-line Therapy for Patients with Advanced Non-small Cell Lung Cancer |
| SHU Xin |
| First-author's address: Department of Oncology, Zunyi First People's Hospital, Zunyi 563000, China |
|
|
|
|
|
|
Received: 18 December 2025
|
|
|
|
|
|
|
